Stock Report

All about this stock under one free report Last Updated: 09-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Landos Biopharma (LABP) Key Ratios

Stock Card factsheet share-fund-plan-icon

$22.91

up-down-arrow $0.11 (0.50%)

As on 23-May-2024 16:37EDT

Market cap

info icon

$72 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

2.1

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -- -- --
EBIT -- -- 66.02 19.21 --
Net Profit -45.40 -59.19 13.70 8.41 -210.25
EPS -45.40 -66.28 39.58 17.56 --
Book Value -- -- -47.32 -- --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-23Dec-22
EBIT-Margin info -215.64-193.03------
Net Margin info ----------
Return on equity info -157.09-56.44-81.55-61.86-65.84
Return on Capital info -157.09-56.44---61.86-65.84
Return on Assets info -56.58-59.33-53.92-52.67-55.01
Debt to Equity (x) info ----0.00----

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
--
-61.86
-65.84
-343.56
75.74
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-81.55

Lower than Peers by 41.22

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
-81.55
-61.86
-65.84
-343.56
75.74
Peer Median
-40.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-53.92

Lower than Peers by 22.68

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
-53.92
-52.67
-55.01
-62.05
-74.60
Peer Median
-31.24
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

--

--

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
--
--
--
-215.64
-170.42
Peer Median
-82.60
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

--

--

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
--
--
--
-212.37
-167.47
Peer Median
-91.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

--

--

Year on year growth in net sales

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
--
--
-1.00
--
--
Peer Median
54.03
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

66.02

Higher than Peers by 67.04

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
66.02
--
-4.50
-26.54
-130.82
Peer Median
-1.02
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

13.70

Higher than Peers by 21.23

Year on year growth in profit after tax

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
13.70
42.26
0.61
-26.81
-116.38
Peer Median
-7.53
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

39.58

Higher than Peers by 25.35

Year on year growth in earnings per share

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
39.58
0.63
0.01
-0.23
-0.80
Peer Median
14.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-48.57

Lower than Peers by 38.43

Year on year growth in book value per share

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
-48.57
--
--
--
--
Peer Median
-10.13
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

4.43

Lower than Peers by 1.38

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
4.43
6.09
7.39
5.55
2.71
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

4.43

Lower than Peers by 1.26

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
4.43
--
--
--
2.58
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-13.08

Lower than Peers by 11.00

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
-13.08
--
-70.30
-94.21
-67.42
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
--
--
--
--
0.86
Peer Median
19.01
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

--

--

Sales / Average Total Assets

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
--
--
--
0.29
0.45
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
--
--
--
3.12
1.57
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
--
--
--
2,605.20
3,727.15
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
--
--
5,172.69
20,045.89
14,202.09
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
--
--
--
-17,437.56
-10,473.37
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
--
-1.04
-0.05
-0.51
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

2.11

Lower than Peers by 3.22

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
2.11
0.71
0.05
0.25
--
Peer Median
5.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

0.29

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
0.29
0.65
1.06
1.85
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

72

Lower than Peers by 70

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Landos Biopharma (LABP)
72
--
--
--
--
Peer Median
142
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...